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Abstract
Microparticles (MPs) are submicron vesicles released from the plasma membrane of eukaryotic 
cells in response to activation or apoptosis. MPs are known to be involved in numerous biologic 
processes, including inflammation, the immune response, cancer metastasis, and angiogenesis. 
Their earliest recognized and most widely accepted role, however, is the ability to promote and 
support the process of blood coagulation. Consequently, there is ongoing interest in studying MPs 
in disorders of hemostasis and thrombosis. Both phosphatidylserine (PS) exposure and the 
presence of tissue factor (TF) in the MP membrane may account for their procoagulant properties, 
and elevated numbers of MPs in plasma have been reported in numerous prothrombotic 
conditions. To date, however, there are few data on true causality linking MPs to the genesis of 
thrombosis. A variety of methodologies have been employed to characterize and quantify MPs, 
although detection is challenging due to their submicron size. Flow cytometry (FCM) remains the 
most frequently utilized strategy for MP detection; however, it is associated with significant 
technological limitations. Additionally, pre-analytical and analytical variables can influence the 
detection of MPs by FCM, rendering data interpretation difficult. Lack of methodologic 
standardization in MP analysis by FCM confounds the issue further, although efforts are currently 
underway to address this limitation. Moving forward, it will be important to address these 
technical challenges as a scientific community if we are to better understand the role that MPs 
play in disorders of hemostasis and thrombosis.
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Introduction
Historical Perspective
Microparticles (MPs) were first described by Chargaff and West [1] in the mid-20th century 
as a “precipitable factor” present in plasma that could promote coagulation processes. Wolf 
[2] in 1967 described “platelet dust” that was formed as a result of platelet shedding, which 
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also exhibited procoagulant activity and was detectable in the 0.1 to 0.3 μm size range by 
transmission electron microscopy in the precipitate of ultracentrifuged plasma. Now 
understood to be platelet MPs (PMPs), this observation has led to an exponential growth in 
the study of MPs derived from platelets and other cell types, and with it a greater 
understanding of their overall biologic relevance. Although the study of MPs has now 
expanded beyond the realm of coagulation and into other areas of (patho)physiology, 
significant research effort remains focused on this aspect of MP function. As depicted in 
Figure 1, total MP publications have increased steadily over the past decade, with 
coagulation-related MP publications showing a similar increase and continuing to represent 
a significant portion of the total MP publications.
Definition
MPs are defined as heterogeneous, submicron (0.1 to 1 μm) vesicles released from cell 
membranes in response to specific stimuli or apoptosis. They have an intact phospholipid 
membrane and express membrane antigens specific to their cell of origin [3]. The working 
definition of a MP generally includes both the size discrimination, as well as the presence of 
externalized phosphatidylserine (PS) on the membrane [4, 5]. Newer evidence, however, 
supports the notion that not all MPs expose PS on their surface [6–10], and that PS content 
may vary depending on the cell of origin and stimulus or mechanism by which they are 
formed [11]. Whether this is due to a true lack of PS exposure, or whether PS expression is 
below the detection threshold of conventional techniques, particularly on smaller MP 
subsets, is unclear [12]. To complicate matters, it has also been theorized that the presence 
of a cell-specific antigen on the surface of a MP does not necessarily identify its cell of 
origin. Soluble antigens from other cell types may adhere to MPs, or fusion may occur 
between MPs from one cell type with the cellular membrane of a different cell, thereby 
allowing the detection of a MP expressing an “adopted” antigen [13, 14].
MPs must also be distinguished from two other bioactive vesicles released from cells. 
Exosomes are preformed vesicles < 100 nm that are generated in endocytic multivesicular 
bodies and released via exocytosis. They are more homogeneous in size than MPs, carry 
different membrane antigens, and play an important role in the immune response [15–19]. 
Conversely, apoptotic bodies (AptB) are produced during the latter stages of cell apoptosis 
[20]. They are typically larger than MPs (1–3 μm), although a few may be smaller (0.5 μm) 
[21]. Similar to MPs, they express PS on their surface; however, in contrast to MPs, AptB 
carry DNA and histones, which is one of their hallmarks [21, 22]. It should be pointed out 
that the term “extracellular vesicles” is increasingly being used in the scientific literature and 
is a term that encompasses MPs exosomes, and AptB [23]. Additionally, the term 
microvesicle is frequently encountered and in general is synonymous and interchangeable 
with the term MP [24].
Cellular Sources and Formation
Circulating MPs are most commonly derived from blood and endothelial cells, although 
other sources, such as tumor cells [25], are capable of producing MPs that appear in blood. 
In healthy individuals, PMPs have generally been accepted to be the most abundant MP 
subtype [26, 27]. More recent data, however, suggest that a significant portion of PMPs may 
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actually be derived from megakaryocytes in bone marrow [28]. To identify specific MP 
subsets by flow cytometry (FCM) according to their cell of origin, antibodies to common 
antigens of the parent cell are typically used (Table 1 and Figure 2), often in combination 
with Annexin V or another marker for PS, such as lactadherin.
The formation and release of MPs from cells typically occurs upon stimulation or induction 
of apoptosis. It is considered a broad primitive response to stress shared by all eukaryotic 
cells [29] and is thought to reflect a dynamic balance between cell proliferation, stimulation 
and death [30]. Specific stimuli known to induce MP formation include activation by 
substances such as endotoxin or cytokines, and partial or complete lysis such as by 
complement, oxidative injury, and high shear stress [31, 32]. Mechanistically, evidence 
continues to emerge regarding the cellular processes that lead to formation and release of 
MPs. In brief, loss of cellular membrane phospholipid asymmetry with resultant PS 
exposure appears to be a critical component of MP formation [33]. This process is governed 
by several phospholipid transporters (“flippase”, “floppase” and “scramblase”), which under 
basal conditions preserve the normal phospholipid asymmetry of the cellular membrane, 
with the negatively charged PS confined primarily to the inner leaflet. Calcium influx also 
appears to be a necessary prerequisite for MP formation, as it contributes to both PS 
externalization, as well as membrane cytoskeleton remodeling through activation of calpains 
and caspases necessary for cleavage of cytoskeletal proteins [34]. Upon stimulation, the loss 
of phospholipid asymmetry along with cytoskeletal disruption eventually leads to membrane 
blebbing and MP formation and release.
Biological Functions of Microparticles
Microparticles and Coagulation – Mechanistic Insight
This section of the review will briefly summarize what is known about MPs and their 
contribution to coagulation processes, as this information provides a backdrop for better 
understanding their potential relevance in disorders of hemostasis and thrombosis. This topic 
has also been extensively reviewed recently [35]. In basic terms, coagulation refers to the 
processes that regulate blood clot formation, whether it be under physiologic conditions to 
prevent hemorrhage (hemostasis) or under pathologic conditions (thrombosis). Additionally, 
coagulation processes can be further divided into those that promote blood clotting 
(procoagulant) and those that counterbalance or regulate blood clotting (anticoagulant and 
fibrinolytic).
The potential procoagulant function of MPs may be related to the presence of PS on the 
outer membrane, as well as the possible presence of tissue factor (TF). MP-associated PS 
provides a catalytic surface for the assembly of enzymatic coagulation complexes that 
initiate and maintain coagulation [36]. This function may underlie the contribution of MPs 
to both the physiologic process of hemostasis as well as the pathologic process of 
thrombosis [37]. Interestingly, it has been estimated that a PMP generated ex vivo has 50- to 
100-fold higher procoagulant activity than the same area on an activated platelet [38], which 
may help account for the potential thrombogenicity of certain MPs. TF is the principal 
physiological initiator of coagulation in vivo through its interactions with the coagulation 
protease Factor VII/VIIa and is constitutively expressed by most vessel wall component 
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cells other than endothelium [39]. It is often therefore described as a “hemostatic envelope” 
that surrounds the vasculature, preventing excessive hemorrhage upon injury. Circulating TF 
in the blood may, however, be present at very low concentration, with monocytes believed 
to be the primary source [40]. The presence of TF on some monocyte-derived MPs (MMPs) 
and tumor-derived MPs is well established; however, whether PMPs or endothelial MPs 
(EMPs) express biologically active TF remains a matter of debate [41, 42]. Although likely 
only a small fraction of total TF in the blood (most of which is likely to be cell-bound), MP-
borne TF is thought to be functionally active and may thus contribute to the procoagulant 
nature of MPs.
More recent data also point to a role for MPs supporting coagulation independent of TF and 
the extrinsic pathway of coagulation. PMPs and red cell MPs (RMPs) generated ex-vivo 
have been shown to initiate and support thrombin generation through the intrinsic pathway 
in a Factor XII-dependent manner [43], meaning that the procoagulant properties of MPs are 
abolished when Factor XII is inhibited. Similarly, RMPs in sickle cell disease [44] and in 
banked units for transfusion [45] have also been shown to promote coagulation through the 
intrinsic pathway in a Factor XI-dependent manner, again through abolished MP 
procoagulant properties when Factor XI is inhibited. These findings shed new light on the 
procoagulant repertoire of MPs and their possible impact through alternative mechanisms in 
coagulation initiation, although further studies are needed for verification as well as to 
elucidate the mechanism by which this occurs. With the renewed interest in the possible role 
of the intrinsic pathway in thrombosis [46, 47], additional studies are also needed to define 
the role MPs might play in this context.
In addition to the procoagulant functions of MPs, evidence exists regarding their ability to 
regulate coagulation through anticoagulant or fibrinolytic mechanisms. MPs have been 
demonstrated to harbor functionally active tissue factor pathway inhibitor (TFPI) on their 
membrane [48, 49], and support activated protein C and protein S mediated regulation of 
coagulation [50–52], both of which are normal anticoagulant pathways in the blood. Newer 
evidence also establishes that MPs support plasmin generation [53, 54], another regulatory 
mechanism by which fibrin clots are degraded. These more recent discoveries point to a 
more complex role of MPs in coagulation, where it is likely that the balance between pro- 
and anticoagulant properties ultimately determines their net effect in hemostasis and 
thrombosis (Figure 3).
Role of Microparticles in Thrombosis
As a corollary to studies that have investigated mechanisms by which MPs may contribute 
to the process of coagulation, the role of MP participation directly in the process of 
pathologic thrombosis in vivo has also received attention. Utilizing a mouse model of 
arteriolar thrombosis, it has been demonstrated that TF+ MPs (presumably MMPs) 
accumulate at the site of thrombus formation and participate in clot propagation [55]. Other 
studies utilizing mouse models of venous thrombosis have additionally implicated MPs [56, 
57]. Although these data are important, they have limitations due to the imperfect nature of 
murine models of thrombosis [58], which either use vessel injury or ligation to initiate 
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thrombus formation. Additionally, exogenous MPs are often infused in these studies, which 
may also limit the applicability of these findings to human thrombotic disorders.
Thus, there is ample evidence to assert that MPs play a biologically plausible role in 
coagulation disorders, and in the remainder of this review we will focus on the literature 
addressing MP analysis by FCM in disorders of hemostasis and thrombosis, as well as the 
technical challenges and limitations encountered when using this approach.
Phenotypic vs Functional Assays for Microparticle Analysis
FCM remains the most commonly utilized approach for the detection and analysis of MPs 
[59]. This platform is advantageous in that it provides not only quantitative information but 
also qualitative information by immunophenotyping particles and thereby identifying their 
cellular origin. Numerous other modalities have also been used for MP analysis, including 
immunoassays, atomic force microscopy, electron microscopy, dynamic light scattering, and 
impedance-based FCM [60]. These methodologies will not be reviewed further; however, 
each has its own advantages and disadvantages. In general, though, these techniques are 
either not widely available, are low throughput, or do not provide both qualitative and 
quantitative data.
It is also worth briefly discussing functional assays that have been used in the study of MPs 
in coagulation disorders. Generally speaking, these assays assess MP pro- or anti-coagulant 
functions. MPs are isolated from plasma using either capture techniques or 
ultracentrifugation and are interrogated for their ability to support or inhibit coagulation 
using either clot-based or chromogenic endpoint assays. TF-dependent procoagulant activity 
can be assessed through the use of a specific blocking antibody to TF [61].
There are limited data on the correlation between functional assays and flow cytometric 
analysis of MPs; however, what data do exist are inconsistent. Several studies have shown a 
positive correlation between MPs detected by FCM and MP procoagulant activity [62, 63], 
while others have failed to demonstrate a correlation [13, 64, 65]. The lack of a positive 
correlation between FCM and functional assays is not surprising, since more sensitive assays 
(such as atomic force microscopy) detect upwards of 1000-fold more MPs than conventional 
FCM [66]. Additionally, dynamic light scattering has shown the median size of MPs to be 
under 300 nm, with the fraction of MPs < 200 nm in plasma accounting for at least 50% of 
the thrombin generating capacity [67]. Since FCM does not detect these smaller MPs, it is 
understandable why functional assays and FCM may fail to correlate. It also appears that the 
plasma centrifugation protocol may influence assay correlations, as increased numbers of 
contaminating platelets prior to freezing will erroneously lead to an improved correlation 
[68]. This is explained by the presence of a greater number of larger PMPs from fractured 
platelets that are then detectable by FCM. More investigation in comparing the two types of 
assays is warranted, but functional assays remain a useful tool in supplementing FCM when 
evaluating MPs in disorders of coagulation.
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Microparticle Analysis in Disorders of Hemostasis
One might assume that a lack or decrease in circulating MPs could contribute to a clinically 
relevant bleeding phenotype, and in fact, this has been shown to be the case. Scott Syndrome 
is a very rare genetic disorder characterized by impaired outward transmembrane migration 
of PS on cell surfaces, including platelets. Individuals with this condition have a moderate 
bleeding tendency due to impaired ability to carry out enzymatic coagulation processes on 
the platelet and/or MP surface [69]. Flow cytometric analysis has demonstrated markedly 
decreased levels of circulating MPs in affected patients [70], which is intuitive given that PS 
externalization is an important step in MP formation. To what degree the lack of MPs in 
these patients directly contributes to their bleeding symptoms is not known, but this 
hypothesis seems likely given the proposed importance of PMPs in hemostasis [71].
Several studies have also examined a potential role of MPs in hemostasis in congenital 
bleeding disorders. Hemophilia A is a rare inherited bleeding disorder characterized by 
deficiency of coagulation Factor VIII (FVIII), which in its severe form results in 
spontaneous hemorrhage [72]. Current treatment involves replacement of the deficient 
coagulation factor using infusions of recombinant or plasma derived FVIII concentrates 
[73]. One study evaluated MPs by FCM in hemophilia A patients before and after receiving 
FVIII infusion for a documented clinical bleeding event. The authors observed a significant 
decrease in total MPs, PMPs and EMPs after treatment [74]. It was suggested that MP 
incorporation into a developing hemostatic plug at the site of injury explained their 
decreasing numbers after treatment.
Von Willebrand disease (VWD) is another congenital bleeding disorder characterized by 
either a qualitative or quantitative deficiency of von Willebrand factor (VWF). It is 
characterized primarily by mucocutaneous bleeding [75]. Therapy typically consists of 
infusing plasma derived VWF containing concentrates or desmopressin (aka DDVAP) 
during acute bleeding episodes [76]. DDAVP promotes hemostasis by increasing 
endogenous levels of VWF and FVIII [77], and by increasing platelet activation [78]. The 
number of PMPs and VWF-bound MPs increases significantly after DDAVP administration 
[79], in conjunction with increased VWF functional activity in plasma. Furthermore, 
depletion of MPs from plasma significantly decreases the VWF functional activity observed 
after DDAVP administration. These data provide evidence that DDAVP administration 
increases MP numbers, including VWF-bound MPs, and that this MP-VWF contributes to 
the increased VWF functional activity. Thus, MPs appear to contribute to the therapeutic 
efficacy of DDAVP in the treatment of VWD.
Microparticle Analysis in Thrombotic Disorders
To date, there has been much more interest in studying MPs in thrombotic disorders (as 
opposed to disorders of hemostasis), and increased circulating MPs have been reported in 
many inherently prothrombotic conditions (Table 2). Additionally, MP numbers are often 
correlated with markers of an activated coagulation system, and in some cases with the 
presence or absence of a historical thrombotic event. These studies are almost exclusively 
retrospective or cross-sectional, and therefore need to be interpreted with caution. While the 
existence of an association between elevated MP numbers and prothrombotic conditions has 
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been repeatedly reported, a causal relationship between increased circulating MPs and 
thrombotic events cannot necessarily be concluded.
A specific area that has received considerable attention is cancer-associated thrombosis. In 
general, increased MPs have been detected using numerous methodologies, including FCM 
in patients with a variety of tumors [80–85]. Several studies have also shown a relative 
increase in MPs in cancer patients with thrombosis compared to cancer patients without 
thrombosis [86–89]. These data pertain primarily to procoagulant functional analysis of 
MPs; however, at least one study has shown increased TF+ MPs by FCM [90].
There are some prospective data in cancer that have linked elevated levels of MPs with 
future occurrence of thrombosis [88, 91–93]. One study showed that TF+ MPs detected by 
FCM was predictive of thrombosis in brain tumor patients [94]. However, other studies 
failed to show increased MPs as predictive biomarkers of future thrombosis [82, 95, 96]. 
The reason for these discrepant results is not clear, but may be related to either variability in 
thrombotic risk with different malignancies or differences in methodologies and analytical 
variables. Although prospective in nature, these data have limitations due to lack of serial 
MP measurements over time. In that regard, probably the most convincing evidence linking 
MPs to cancer-associated thrombosis comes from a study that prospectively examined serial 
MP TF-dependent procoagulant activity (MP-TF activity) in pancreatic cancer patients [97]. 
Herein, there was a significant correlation between increasing levels over time and 
subsequent development of thrombosis; however, the study conclusions were limited due to 
its small size.
There have also been quite discrepant studies evaluating MPs in the setting of thrombosis 
without an underlying prothrombotic condition (ie. idiopathic thrombosis). Several cross 
sectional studies have reported increased MP procoagulant functional activity [98, 99], while 
others have shown increased MPs by FCM [90, 99–102]. Still other studies failed to 
demonstrate an increase in MPs, either using functional assays [103–105] or FCM [106, 
107]. Again, these contradictory results are most likely attributable to differences in 
methodologies and techniques.
Challenges in Flow Cytometric Analysis of Microparticles
Despite FCM being the most frequently utilized methodology for the analysis of MPs, 
numerous challenges exist, in large part related to limitations in the ability to detect 
submicron particles. Additionally, differences in how samples are processed and analyzed 
can have significant impact on the results obtained. Thus, important factors related to the 
analysis of MPs can be divided into pre-analytical and analytical variables (Table 3).
Pre-Analytical Variables in Microparticle Analysis
Numerous pre-analytical variables, most of which pertain to the collection and handling of 
specimens, can directly impact MP analysis. Although these variables can theoretically 
affect results regardless of the detection methodology, the majority of information 
addressing pre-analytical variables has been identified in studies utilizing FCM. Major pre-
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analytical variables include the method of blood collection including type of anticoagulant 
used, timeframe and method for processing samples, and method of sample storage.
(i) Blood Collection—Several issues regarding the method of blood collection can 
contribute to an artifactual elevation in MP numbers. Use of a tourniquet, traumatic 
venipuncture, small-diameter needles, and use of vacuum-filled containers may cause 
hemolysis, platelet activation or endothelial damage, all of which can falsely increase the 
number of MPs detected. It is therefore standard practice to discard the first several 
milliliters of blood to minimize these variables [11]. The type of anticoagulant used for 
blood collection may also have effects on MP analysis. Specifically, heparin has been shown 
to cause increased MP numbers compared to other anticoagulants [108]. Additionally, PMP 
levels can increase due to ex-vivo vesiculation of platelets in citrate, with no such increase 
observed in samples obtained in citrate-theophylline-adenosine-dipyridamole [109] or acid-
citrate dextrose [110], although sample agitation makes this much more pronounced [111]. 
In general, however, citrate is most commonly used due to its wide availability and 
acceptable results, provided that sample agitation and delays in processing are avoided.
(ii) Sample Processing—MP analysis is generally performed on plasma samples, 
although can also be done in whole blood [112] or on isolated MPs [107]. Although data 
directly comparing MP numbers assessed in each sample type from the same individual are 
lacking, it is likely that the results would be variable across techniques. Particularly when 
MPs isolated from plasma by ultracentrifugation are re-suspended for analysis, aggregation 
of MPs is highly likely to occur using such high centrifugation speeds, thus changing their 
size profile and altering the number of detectable MPs within the appropriate size-based 
gate. As such, it is recommended that MP analysis be performed in plasma. Delays in 
plasma preparation should also be avoided to help prevent the ex-vivo generation of MPs 
from blood cells.
For plasma MP analysis, the centrifugation protocol is highly important. Numerous 
centrifugation protocols have been employed [113], resulting in either platelet-poor or 
platelet-free plasma. Depending on the centrifugation speed, there is either the potential for 
loss of MPs in the sediment or the supernatant, as well as the risk of contamination of the 
sample with residual platelets. During a freeze/thaw cycle, these residual platelets can be 
fractured, leading to artificially increased PMP numbers [111, 114]. When MP analysis is 
performed on fresh samples, there is probably minimal effect on the results unless the 
centrifugation speed is high enough to pellet a portion of the MPs with the cellular fraction. 
Overall, the goal is to avoid loss of MPs, thus maintaining sensitivity, without sacrificing 
specificity through the contamination of samples with residual platelets and resultant false 
increase in MP numbers.
Another potential pitfall is the possibility for “micro-clot” formation to occur in the plasma 
prior to analysis. This typically occurs with Annexin V staining, which requires the addition 
of calcium to plasma samples anticoagulated with calcium chelators (such as citrate). The 
addition of calcium also enables the enzymatic processes of coagulation to occur, which can 
lead to formation of a fibrin clot [115]. These “micro-clots” can then bind MPs, creating 
large aggregates that fall outside the MP size gate and thus artificially reduce the number of 
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MPs detected. The use of heparin for blood collection has been proposed as a solution to this 
problem, since it inhibits coagulation and prevents “micro-clot” formation [116]. 
Alternatively, an anticoagulant such as Hirudin, a direct thrombin inhibitor, can be 
incorporated into the calcium-containing Annexin V buffer to prevent this artifact, which 
also avoids the known increase in MPs that occurs when blood samples are collected in 
heparin. This latter method is currently being utilized in the most recent standardization 
workshop for flow cytometric evaluation of MPs sponsored by the International Society on 
Thrombosis and Haemostasis (ISTH).
(iii) Handling and Storage Practices—The method of transportation of samples and 
potential agitation during transport are thought to influence MP numbers, particularly in 
blood samples anticoagulated with citrate, due to ex-vivo generation of MPs from blood 
cells. More widely recognized, however, is the impact of storage methods on MP analysis. 
Several studies have shown an increase in MP numbers when comparing frozen to fresh 
samples [117, 118], although this increase appears to be minimal over a 12 month period 
[111]. There is also the theoretical risk of fracturing MPs, causing an artificial increase in 
overall MP numbers [106]. Ideally, fresh plasma samples should be analyzed immediately to 
avoid this artifact. However, in addition to being impractical, labor-intensive and inefficient, 
this restriction would severely limit the ability for collaborative studies.
Analytical Variables in Microparticle Analysis
Several analytical variables can also affect the detection and enumeration of MPs by FCM. 
The most obvious of these is the type of flow cytometer used for MP evaluation and its 
intrinsic ability to discriminate submicron particles. Newer generation flow cytometers have 
improved detection capabilities in the 200–300 nm range and should be the preferred option 
when studying MPs [119], although the use of older generation flow cytometers with 
suboptimal resolution is still common practice. Apart from the type of flow cytometer used, 
other analytical variables include gating strategies for both size and fluorescence and the use 
of counting beads for enumeration.
(i) Size Gating—Initial gating for MP analysis is typically based upon size through the use 
of calibration beads. Generally, a bead that approximates 1 μm is used to set the upper size 
limit for MP detection, and all events smaller in size are interrogated for PS and/or cellular 
antigens using fluorescently labeled antibodies. Plastic beads, however, remain an imperfect 
model for size calibration since factors other than size can influence FSC, including relative 
refractive indices of both particles and suspension medium, presence of surface absorptive 
material, particle shape, and surface roughness [120, 121], which are not equivalent between 
biological entities and beads. This has led to controversy over their appropriate application 
and use [122–125]. A proposed solution to this problem is the use of biological entities, such 
as bacteria or viruses, for size calibration, although this strategy would also need 
standardization [123, 124].
(ii) Fluorescence Gating—Another challenging analytical variable is discriminating a 
positive fluorescent signal from background when using fluorescently labeled antibodies. 
Most laboratories use isotype controls (ITCs) to aid in setting gates for positive vs. negative 
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events. This technique has classically been used for cellular phenotyping, but in recent years 
its use even in this field has been challenged [126–128]. Although intended to account for 
background fluorescence and nonspecific binding, different ITCs can manifest various levels 
of background staining depending on their concentration, degree of aggregation, and 
fluorophore:antibody ratio [129]. Furthermore, the degree of nonspecific binding of an ITC 
may or may not reflect an equivalent degree of nonspecific binding as that of the antibody of 
interest. Therefore, the indiscriminant use of ITCs can significantly affect the number of 
positive events detected [130]. Adding to the complexity is the fact that many of the 
antigens used for fluorescent labeling, such as those on leukocyte and endothelial MPs, are 
weakly expressed and do not provide a clear separation in fluorescence between positive and 
negative events, rendering the use of ITCs even more troublesome. As such, titration of 
ITCs against the specific antibody of choice at its intended concentration should always be 
done in an antigen free sample to match background fluorescence of the ITC to that of the 
specific antibody. Options for antigen free samples include MP free plasma obtained 
through the use of detergents to lyse MPs [131] or via ultracentrifugation. Additionally, 
titration of specific antibodies should also be done to ensure optimal concentration and to 
help limit the effects of nonspecific antibody binding [132, 133]. Lastly, all antibodies and 
ITCs should undergo ultracentrifugation prior to use to pellet free fluorochrome aggregates, 
which can be detected in the MP size gate and interpreted as a false positive fluorescent 
signal [134].
(iii) Counting Beads and Enumeration—Counting beads are commonly used for the 
enumeration of MPs by FCM. These calibrated bead solutions have a known concentration 
and typically fluoresce brightly in a wide range of excitation and emission wavelengths. A 
known volume of beads is added to a sample, and by comparing the ratio of bead events to 
MP events, absolute numbers of MPs can be calculated. Although a useful tool, caution is 
needed when using counting beads for enumeration of submicron particles. Designed 
primarily for cell counting, the available beads are typically in the 5–10 micron size range. 
Therefore, when analyzing MPs, particularly if pushing the detection threshold to its lower 
limits, the flow cytometer may not have the dynamic range necessary to accurately detect 
and count the beads. To help avoid this potential pitfall, counting beads should always be 
assessed using thresholds and settings for both MP analysis and large particle (ie. cellular) 
analysis to ensure that similar numbers of beads are counted with each set of parameters. 
Additionally, counting beads on the smaller end of the size spectrum should be chosen for 
MP analysis to help lessen the chance for error.
Accurate enumeration of MPs can also be complicated by “swarm effect” as recently 
described by van der Pol and colleagues [135]. Swarm effect is encountered when multiple 
small particles, which alone are below the detection threshold of the cytometer, are 
simultaneously present in the laser beam and thus generate a single event signal. In this 
situation, the flow cytometer-determined concentration of particles underestimates the true 
concentration, and the relationship between count rate and prepared concentration is non-
linear. This detection of coincident events can be controlled for by optimization of flow rates 
and dilutions [136], and therefore it is important to use low flow rates and optimal sample 
dilutions in order to avoid or minimize this complication. The advent of imaging flow 
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cytometry appears to enable accurate counting of individual MPs regardless of sample 
concentration [137], however this modality is still in its infancy.
The Need for Standardization
Due to the inherent difficulties associated with MP detection by FCM, as well as the 
numerous pre-analytical and analytical variables discussed above, it is clear that 
standardization of practices in flow cytometric analysis of MPs is urgently needed. To that 
end, an attempt at standardization of PMP enumeration was recently undertaken by the 
ISTH. Using a mixture of fluorescent beads of known sizes (Megamix™ – Biocytex, 
Marseille, France) and gating strategies to set both an upper and lower size limit (~500 nm) 
for MP detection, it was shown that a window of MP analysis could be reproducibly set on 
different cytometers of the same model to allow consistent PMP enumeration over time 
[138]. This protocol was then adopted as part of an ISTH workshop in an attempt to validate 
its use, wherein it was shown to facilitate the reproducible enumeration of PMPs across 
different flow cytometers and in different labs, though modifications of the protocol were 
required for certain cytometers [139]. As a next step, a second ISTH workshop has 
attempted to standardize PMP enumeration down to ~300 nm utilizing a similar bead-based 
gating strategy. The results of this exercise are expected in late 2014/early 2015.
In addition to standardization attempts focused on analytical variables, the Vascular Biology 
Scientific sub-Committee of the ISTH also organized a workshop aimed at standardizing 
pre-analytical variables that can critically impact MP measurements and remain a major 
source of variability [140]. Herein it was shown that a standardized pre-analytical protocol 
could reduce the inter-laboratory variability of flow cytometric evaluation of PMPs, 
although variability was not completely eliminated. Together, the results of these workshops 
are promising, although much work is still needed, particularly to help standardize the 
evaluation of MP subsets other than PMPs that are more challenging to detect, such as 
endothelial and leukocyte MPs. Hopefully, however, these efforts will serve as a first step 
towards continued exercises aimed at standardizing methodologies for MP analysis to allow 
better comparison of results across studies and promote the development of collaborative 
studies across centers.
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Figure 1. 
Number of (A) total MP publications, and (B) specific coagulation-related MP publications 
by year since 1990. Total MP publication numbers were acquired utilizing a PubMed search 
for articles from 1990–2014 with keywords “microparticles or microvesicles”, while 
excluding studies related to pharmacology, drug delivery and non-biological entities. 
Coagulation-related MP publication numbers were acquired utilizing a PubMed search for 
articles from 1990–2014 with keywords “microparticles or microvesicles” in conjunction 
with coagulation specific terms such as “thrombosis” and “hemostasis”.
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Figure 2. 
Representative staining and gating strategies for A) platelet microparticles (PMP), B) red 
blood cell microparticles (RMP), and C) monocyte microparticles (MMP) analyzed in 
platelet free plasma on a Stratedigm S1000Ex flow cytometer. Fluorescent gating was 
performed within the MP size gate of 200–900 μm, which was initially set utilizing 
polystyrene beads (data not shown). PMP = dual positive Annexin V/CD41 events. RMP = 
dual positive Annexin V/CD235 events. MMP = dual positive Annexin V/CD14 events.
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Figure 3. Multifaceted role of MPs in coagulation processes
Simplified schemata of the coagulation cascade showing the different potential contributions 
of MPs. MPs support coagulation through exposure of phosphatidylserine (PS), which 
provides a catalytic surface for assembly of the coagulation complexes. Tissue factor (TF) 
bearing MPs can activate coagulation through the extrinsic pathway. MPs may also support 
coagulation through the intrinsic pathway, although the mechanism by which this occurs is 
not fully known. Anticoagulant properties of MPs include the ability to support Protein C/
Protein S mediated regulation of coagulation, as well as tissue factor pathway inhibitor 
(TFPI) mediated inhibition of TF/VIIa activity and FX. MPs can also support plasmin 
generation, an enzyme that solubilizes and degrades clots. (Bolded arrows indicate 
activation steps [ie FXII activates FXI]. Dashed lines indicate inhibitory effects. Unbolded 
arrows emanating from MPs indicate areas of MP participation in coagulation activation 
processes.)
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Table 1
Common antigens used to stain and identify specific MP subsets according to cell of origin
MP subtype Antigen Alternative Name (if applicable)
Platelet microparticles (PMP) CD41
CD42a
CD42b
CD61*
CD62P*
GPIIb
GPIX
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Table 2
Prothrombotic conditions with reported increased microparticles.
Prothrombotic condition References
Sickle cell disease [141–143]
Malignancy [80, 82, 83, 86, 88–90, 93, 94, 97, 144]
Thrombotic thrombocytopenic purpura(TTP) [145, 146]
Antiphospholipid antibody syndrome [147–149]
Sepsis [150–153]
Myeloproliferative disorders [154–157]
Inflammatory bowel disease [158–160]
Nephrotic syndrome [161]
Paroxysmal nocturnal hemoglobinuria [142, 162]
Systemic vasculitis [163, 164]
Pregnancy/Preeclampsia [165–168]
Systemic lupus erythematosus [169–171]
Thrombophilia [172, 173]
Trauma [174–176]
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Table 3
Overview of major challenges related to flow cytometric analysis of MPs.
Important Issues in MP Analysis by Flow Cytometry
Pre-Analytical Analytical/Technical
• Method of blood collection
– Tourniquet use
– Needle diameter
– Type of anticoagulant
• Sample processing
– Sample type (whole blood, plasma, isolated MPs)
– Time to sample preparation
– Centrifugation protocol
– “Micro-clot” formation
• Sample handling and storage
– Sample transportation/agitation
– Fresh vs freeze/thaw
• Flow cytometer
– Intrinsic resolution capabilities
• Size gating
– Beads vs biologicals
• Fluorescence gating
– Proper use of isotype controls (ITCs)
– Detection of dimly expressed antigens
– Titration of antibodies and ITCs
– Fluorochrome aggregates
• MP enumeration
– Use of counting beads
– “Swarm effect”
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